Erratum: Plasma level of lipopolysaccharide-binding protein is indicative of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation (International Journal of Hematology (2012) 95 (680-688) DOI: 10.1007/s12185-012-1076-z);Plasma level of lipopolysaccharide-binding protein is indicative of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

International Journal of Hematology

Volumn 95, Issue 6, 2012, Pages 680-688

  Ye, Haige ^a,b   Lv, Meng ^a   Zhao, Xiaosu ^a   Zhao, Xiangyu ^a   Huang, Xiaojun ^a  

^a PEKING UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Acute graft versus host disease; Hematopoietic stem cell transplantation; Lipopolysaccharide binding protein

Indexed keywords

LIPOPOLYSACCHARIDE BINDING PROTEIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; RASH; SCHOOL CHILD;

EID: 84865017526     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1131-9     Document Type: Erratum

References (24)

1. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009;113:273-8.
2. Scholl S, Sayer HG, Mugge LO, et al. Increase of interleukin-18 serum levels after engraftment correlates with acute graft-versushost disease in allogeneic peripheral blood stem cell transplantation. J Cancer Res Clin Oncol. 2004;130:704-10.
3. Takatsuka H, Takemoto Y, Okamoto T, et al. Predicting the severity of graft-versus-host disease from interleukin-10 levels after bone marrow transplantation. Bone Marrow Transpl. 1999;24:1005-7. (Pubitemid 29532872)
4. Foley JE, Mariotti J, Ryan K, et al. Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells. Biol Blood Marrow Transpl. 2008;14:959-72.
5. Dean RM, Fry T, Mackall C, et al. Association of serum interleukin- 7 levels with the development of acute graft-versus-host disease. J Clin Oncol. 2008;26:5735-41.
6. Penack O, Holler E, van den Brink MR. Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. Blood. 2010;115:1865-72.
7. Elmaagacli AH, Koldehoff M, Hindahl H, et al. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation. Transplantation. 2006;81:247-54.
8. Ye H, Sun L, Huang X, et al. A proteomic approach for plasma biomarker discovery with 8-plex iTRAQ labeling and SCX-LCMS/ MS. Mol Cell Biochem. 2010;343:91-9.
9. Ulevitch RJ, Tobias PS. Recognition of Gram-negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol. 1999;11:19-22. (Pubitemid 29082331)
10. Vreugdenhil AC, Rousseau CH, Hartung T, et al. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol. 2003;170:1399-405. (Pubitemid 36139507)
11. Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest. 2001;107:1581-9. (Pubitemid 32574644)
12. Cooke KR, Hill GR, Crawford JM, et al. Tumor necrosis factoralpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest. 1998;102:1882-91. (Pubitemid 28533836)
13. Levy O, Teixeira-Pinto A, White ML, et al. Endotoxemia and elevation of lipopolysaccharide-binding protein after hematopoietic stem cell transplantation. Pediatr Infect Dis J. 2003;22:978-81. (Pubitemid 37445076)
14. Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transpl. 2006;38:291-7.
15. Rai AJ, Gelfand CA, Haywood BC, et al. HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics. 2005;5:3262-77. (Pubitemid 41192034)
16. Blairon L, Wittebole X, Laterre PF. Lipopolysaccharide-binding protein serum levels in patients with severe sepsis due to grampositive and fungal infections. J Infect Dis. 2003;187:287-91. (Pubitemid 36132642)
17. Levy O, Sisson RB, Fryer HE, et al. Neutrophil defense in patients undergoing bone marrow transplantation: bactericidal/ permeability-increasing protein (BPI) and defensins in graftderived neutrophils. Transplantation. 2002;73:1522-6. (Pubitemid 34547478)
18. Kozak I, Dwilewicz-Trojaczek J, Sieminska J, et al. Risk factors of graft-versus-host disease in patients after allogeneic stem cell transplantation. Wiad Lek. 2011;64:164-9.
19. Zeng L, Gu W, Zhang AQ, et al. A functional variant of lipopolysaccharide binding protein predisposes to sepsis and organ dysfunction in patients with major trauma. Ann Surg. 2012;255:147-57.
20. Keith MS. Graft-vs-host disease. Thomas' hematopoietic cell transplantation, vol 50, 3rd edn, Sect 4. New York: Wiley- Blackwell; p. 635-64.
21. Paczesny S, Braun TM, Levine JE, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010;2:13ra2.
22. Alkemade JA, Molhuizen HO, Ponec M, et al. SKALP/elafin is an inducible proteinase inhibitor in human epidermal keratinocytes. J Cell Sci. 1994;107(Pt 8):2335-42. (Pubitemid 24273501)
23. Nonomura K, Yamanishi K, Yasuno H, et al. Up-regulation of elafin/SKALP gene expression in psoriatic epidermis. J Invest Dermatol. 1994;103:88-91. (Pubitemid 24227577)
24. Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet. 2009;373:1550-61.